MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 third quarter financial results and year-to-date performance on November 8, 2022, at 9:00 AM ET.
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 third quarter financial results and year-to-date performance on November 8, 2022, at 9:00 AM ET.
CEO Michael Castagna and CFO Steven Binder will discuss the results during a conference call, accessible via the company's website. MannKind focuses on innovative therapies for endocrine and lung diseases, utilizing advanced inhalation technologies. For further details, visit their official site.
Positive
- Upcoming conference call may provide insights into financial performance and strategic direction.
Negative
- None.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was +2.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM (Eastern Time) on Tuesday, November 8, 2022.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at https://mannkindcorp.com/news-events/ under Events & Presentations.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.
MannKind Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.